Carmustine, vincristine, and prednisone in the treatment of canine lymphosarcoma.
A chemotherapeutic protocol using carmustine in combination with vincristine and prednisone was tested in dogs with multicentric malignant lymphosarcoma. Of seven dogs treated, six (85.7%) achieved complete remission. A partial response occurred in one dog. Median survival time was 224 days (mean 386 days), and median duration of remission was 183 days (mean 323 days). Marked neutropenia was observed following carmustine administration. There were no significant alterations in platelets and red blood cell counts during treatment, and no abnormalities attributable to the chemotherapy were found in serum biochemical profiles. Results of this study showed that carmustine is an effective alternative option in the treatment of canine lymphosarcoma.
Ricci Lucas
Sílvia Regina
SR
Faculdade de Medicina, Veterinária e Zootecnia, Universidade de São Paulo, Brazil.
Pereira Coelho
Bruna Maria
BM
Marquezi
Maurício Luis
ML
Franchini
Maria Luisa
ML
Miyashiro
Samantha Ive
SI
De Benedetto Pozzi
Diana Helena
DH
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001774:Blood Chemical Analysis / Q000662:veterinary; D002330:Carmustine / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004285:Dogs; D005260:Female; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000662:veterinary*; D008297:Male; D009367:Neoplasm Staging / Q000662:veterinary; D009503:Neutropenia / Q000139:chemically induced / Q000662:veterinary; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D014750:Vincristine; D002330:Carmustine; D011241:Prednisone